Compounds > irofulven
Page last updated: 2024-09-04

irofulven and Cancer of Prostate

irofulven has been researched along with Cancer of Prostate in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's6 (85.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S1
Herman, TS; Kosakowska-Cholody, T; Leal, BZ; Liang, H; Michejda, CJ; Salinas, RA; Waters, SJ; Woynarowska, BA; Woynarowski, JM1
Arsenau, J; Berman, B; MacDonald, JR; Richards, D; Senzer, N; Smith, S1
Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R1
McMorris, TC1
Herman, TS; MacDonald, JR; Roberts, K; Woynarowska, BA; Woynarowski, JM1
Bushong, P; Muñoz, RM; Waters, SJ; Woynarowska BAHigdon, AL1

Reviews

1 review(s) available for irofulven and Cancer of Prostate

ArticleYear
Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.
    Bioorganic & medicinal chemistry, 1999, Volume: 7, Issue:5

    Topics: Animals; Antibiotics, Antineoplastic; Clinical Trials as Topic; Humans; Male; Mice; Models, Chemical; Prostatic Neoplasms; Rats; Sesquiterpenes; Technology, Pharmaceutical; Tumor Cells, Cultured

1999

Trials

1 trial(s) available for irofulven and Cancer of Prostate

ArticleYear
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
    American journal of clinical oncology, 2005, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Survival Analysis

2005

Other Studies

5 other study(ies) available for irofulven and Cancer of Prostate

ArticleYear
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    The Prostate, 2004, Apr-01, Volume: 59, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Xenograft Model Antitumor Assays

2004
Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:11

    Topics: Apoptosis; bcl-2-Associated X Protein; Bridged Bicyclo Compounds; Caspases; Cell Line, Tumor; Cell Proliferation; Cytochromes c; DNA Fragmentation; Enzyme Inhibitors; Humans; Male; Mitochondria; Molecular Structure; Prostatic Neoplasms; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Sesquiterpenes; Signal Transduction

2004
The postchemotherapy PSA surge syndrome.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome

2008
Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells.
    Radiation research, 2000, Volume: 154, Issue:4

    Topics: Adenocarcinoma; Androgens; Antineoplastic Agents, Alkylating; Apoptosis; Combined Modality Therapy; DNA Damage; Gamma Rays; Humans; Intestinal Mucosa; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Sesquiterpenes; Tumor Cells, Cultured; Tumor Stem Cell Assay

2000
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.
    Investigational new drugs, 2001, Volume: 19, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Cell Division; DNA Primers; Gene Expression Regulation, Neoplastic; Humans; Immunoradiometric Assay; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sesquiterpenes; Tumor Cells, Cultured

2001